The U.S. government’s attempts to enforce its ownership of biopharma intellectual property got a setback May 9 when a six-member federal jury in Delaware determined that Gilead Sciences Inc. did not infringe government patents claiming pre-exposure prophylaxis (PrEP) use of Gilead’s HIV drugs, Truvada and Descovy, both of which combine emtricitabine and tenofovir.
Halia Therapeutics Inc. has reported the development of tyrosine-protein kinase receptor TYRO3 inhibitors potentially useful for the treatment of glioma.
Cullgen (Shanghai) Inc. has patented proteolysis targeting chimera (PROTAC) compounds comprising a DDB1 binding moiety covalently bonded to a target protein binding moiety through a linker. They are reported to be useful for the treatment of cancer.
Compounds reported to be useful for the treatment of myotonic 1, myotonic 2 and muscular dystrophy have been described in a City University of New York patent.
Jiangsu Chia Tai Tianqing Pharmaceutical Group Co. Ltd. and Medshine Discovery Inc. have jointly patented pyrimidine tricyclic derivative soluble guanylate cyclase (sGC) activators. They are reported to be useful for the treatment of heart failure and hypertension.
Biosplice Therapeutics Inc. has prepared and tested pyrrolo[2,1-F][1,2,4]triazines derivatives acting as dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitors and reported to be useful for the treatment of cancer, diabetes and neurological disorders.
RSS